Sulpiride
PreclinicalSmall molecule
Sulpiride is one of 79 small molecule programs targeting Cognition. It is currently in Preclinical.
3
Indications
8
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
88 competitors in Cognition
#DrugCompanyPhaseTrials
1Ambien
PPurdue Pharma LP
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Duragesic
CCephalon
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Namenda
AbbViePhase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 2
Remimazolam Tosilate
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Psilocybin
COMPASS PathwaysPhase 2
Ketalar
Boehringer IngelheimPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Antipsychotics1 trial
Drug Monitoring1 trial
Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers
Completed·—·N/A·NCT01777685·16 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulpiride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPhilipps University Marburg